Results of a multi-center phase II study of imatinib and fluorourcail/leucovorin (FU/LV) in patients with unresectable or metastatic gallbladder or biliary tract cancer

被引：0
|
作者：
Schuette, K. [1 ]
Moehler, M. [2 ]
Kettner, E. [3 ]
Hegewisch-Becker, S. [4 ]
Goekkurt, E. [1 ]
Al-Batran, S. [5 ]
Steffens, C. [6 ]
Ehninger, G. [1 ]
Stoehlmacher, J. [1 ]
机构：
[1] Univ Klinikum Carl Gustav Carus, Med Klin 1, Dresden, Germany
[2] Univ Mainz Klinikum, Med Klin, Mainz, Germany
[3] Klinikum Magdeburg, Magdeburg, Germany
[4] Onkol Schwerpunkt Praxis Hamburg, Hamburg, Germany
[5] Krankenhaus Nordw, Med Klin 2, Frankfurt, Germany
[6] Onkol Praxisgemeinschaft, Stade, Germany
来源：
EJC SUPPLEMENTS | 2009年 / 7卷 / 02期
关键词：
D O I：
10.1016/S1359-6349(09)71339-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：395 / 395
页数：1
相关论文
共 50 条
  • [31] Phase II randomized study of oral uracil/tegafur (UFT) plus leucovorin (LV) or parenteral 5-Fluorouracil (5-FU) plus leucovorin in patients with metastatic colorectal cancer (MCRC)
    Sizer, B.
    Makris, A.
    Barone, C.
    Bordonaro, R.
    Hausmaninger, H.
    Steger, G.
    Aloe, A.
    Peeters, O.
    Donato, B.
    ANNALS OF ONCOLOGY, 2004, 15 : 93 - 93
  • [32] COMPARATIVE PHASE 2 STUDY OF INFUSIONAL 5, 10-METHYLENETETRAHYDROFOLATE WITH 5-FLUOROURACIL (FU) VERSUS LEUCOVORIN (LV) WITH FU IN PATIENTS WITH METASTATIC COLORECTAL CANCER
    Cassidy, J.
    Jelic, S.
    Pluzanska, A.
    Ciuleanu, T.
    Babu, K. G.
    Stewart, J.
    Schupp, J. P. H.
    ANNALS OF ONCOLOGY, 2008, 19 : 130 - 130
  • [33] A multicenter phase Ib/ II study of liposomalirinotecan, 5-fluorouracil (5-FU), and leucovorin (LV) with nivolumab as second-line therapy for patients with advanced biliary tract cancer (BilT-03)
    Sahai, Vaibhav
    Griffith, Kent A.
    Lin, Bruce Shih-Li
    Soares, Heloisa P.
    Chandana, Sreenivasa R.
    Crysler, Oxana V.
    Enzler, Thomas
    Zalupski, Mark
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [34] Safety and Efficacy of Modified FOLFIRINOX in Unresectable or Metastatic Gallbladder Cancer: A Phase II Pilot Study
    Sharma, Atul
    Pramanik, Raja
    Kumar, Akash
    Pathy, Sushmita
    Kumar, Sunil
    Bhoriwal, Sandeep
    Thulkar, Sanjay
    Dash, Nihar Ranjan
    Pal, Sujoy
    Choudhary, Priyanshu
    Pawar, Satyajit
    Kumar, Rakesh
    Gupta, Gaurav
    JCO GLOBAL ONCOLOGY, 2021, 7 : 820 - 826
  • [35] Phase II study of oxaliplatin, UFT, and leucovorin in patients with metastatic gastric cancer
    Siemerink, Ester J. M.
    Drenth, Annemieke F. J.
    Mulder, Nanno H.
    Plukker, John T. M.
    Hospers, Geke A. P.
    GASTRIC CANCER, 2010, 13 (02) : 95 - 100
  • [36] Phase II study of oxaliplatin, UFT, and leucovorin in patients with metastatic gastric cancer
    Ester J. M. Siemerink
    Annemieke F. J. Drenth
    Nanno H. Mulder
    John T. M. Plukker
    Geke A. P. Hospers
    Gastric Cancer, 2010, 13 : 95 - 100
  • [37] SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma
    Anthony B. El-Khoueiry
    Cathryn J. Rankin
    Edgar Ben-Josef
    Heinz-Josef Lenz
    Philip J. Gold
    R. Darryl Hamilton
    Rangaswamy Govindarajan
    Cathy Eng
    Charles D. Blanke
    Investigational New Drugs, 2012, 30 : 1646 - 1651
  • [38] SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma
    El-Khoueiry, Anthony B.
    Rankin, Cathryn J.
    Ben-Josef, Edgar
    Lenz, Heinz-Josef
    Gold, Philip J.
    Hamilton, R. Darryl
    Govindarajan, Rangaswamy
    Eng, Cathy
    Blanke, Charles D.
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (04) : 1646 - 1651
  • [39] Phase II study of oxaliplatin, 5-FU and leucovorin in patients with relapsed ovarian cancer
    Thomas, AL
    Osman, A
    Morgan, B
    Khanna, S
    Symonds, RP
    O'Byrne, K
    BRITISH JOURNAL OF CANCER, 2001, 85 : 57 - 57
  • [40] Final results from the NIFTY trial, a phase IIb, randomized, open-label study of liposomal Irinotecan (nal-IRI) plus fluorouracil (5-FU)/leucovorin (LV) in patients (pts) with previously treated metastatic biliary tract cancer (BTC)
    Yoo, C.
    Kim, K-P.
    Kim, I.
    Kang, M. J.
    Cheon, J.
    Kang, B. W.
    Ryu, H.
    Jeong, J.
    Lee, J. S.
    Kim, K. W.
    Ryoo, B-Y.
    Abou-Alfa, G. K.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S565 - S565
12345